Latanoprostene bunod: Phase III started

NicOx disclosed in its 2Q13 earnings that Bausch + Lomb began the open-label, Japanese Phase III JUPITER trial to evaluate once-daily 0.024% latanoprostene bunod for 1 year in about 130 patients with ...